Odyssey Therapeutics filed terms for a $225 million IPO on Tuesday, offering 15 million shares at $14 to $16 per share. The Boston-based biotech develops precision medicines for autoimmune diseases and expects to list on Nasdaq under the ticker ODTX by Friday. Morgan Stanley and Jefferies are leading the offering.
The company carries three assets into public markets: ZCTA-01, a monoclonal antibody targeting a novel immune checkpoint in Phase 1 for systemic lupus; ZCTA-03, a small molecule inhibitor for ulcerative colitis entering Phase 1 next quarter; and an undisclosed preclinical program. Odyssey burned $87 million in cash during the nine months ended September 2024 and reported $142 million in cash at quarter-end. The company posted a $91 million net loss for that period on zero revenue. Management projects the IPO proceeds plus existing cash will fund operations into Q3 2026, enough to deliver Phase 1b data for ZCTA-01 and initiate two additional trials.
The offering matters because autoimmune biotech has tightened into oligopoly at the top while early-stage names struggle for non-dilutive capital. AbbVie's Skyrizi and Rinvoq franchise posted $14.2 billion in combined 2024 sales, up 41% year-over-year, creating a gravitational pull for institutional buyers toward established brands. Odyssey's $1.05 billion post-money valuation at midpoint prices the company at 12x its current cash position, a multiple that works only if ZCTA-01 data arrives clean and on time. Bain Capital Life Sciences owns 38% pre-offering and will retain 31% post-deal, a concentration that limits float and amplifies volatility in the first six months of trading. The company's burn rate implies 16 months of runway post-IPO without additional financing, which means a secondary offering or partnership announcement likely arrives before the ZCTA-01 Phase 2 readout in mid-2026.
Allocators should track three events: the ZCTA-01 Phase 1b safety data expected in Q1 2025, which will determine whether institutions build positions or fade the name; the ZCTA-03 Phase 1 initiation in Q2 2025, which tests management's ability to execute on multiple programs simultaneously; and any partnership or licensing discussions around the undisclosed preclinical asset, which could provide non-dilutive capital before the next secondary. The competitive landscape tightens in Q4 2025 when two other autoimmune biotechs—Prometheus Biosciences under Merck and Ventyx Biosciences—report mid-stage data that will reset valuation benchmarks across the sector.
The IPO prices into a market that has already absorbed $4.1 billion in biotech offerings this quarter, with 72% of those deals trading below issue price after 90 days. Odyssey's execution risk is timing, not science.